ELIAS JOSEPH JABBOUR to Injections, Subcutaneous
This is a "connection" page, showing publications ELIAS JOSEPH JABBOUR has written about Injections, Subcutaneous.
Connection Strength
0.105
-
Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Ann Hematol. 2020 Oct; 99(10):2215-2229.
Score: 0.045
-
Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes. J Clin Oncol. 2013 Jul 10; 31(20):2548-53.
Score: 0.027
-
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome. Cancer. 2007 Jan 15; 109(2):265-73.
Score: 0.017
-
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986. Cancer. 2005 Jun 15; 103(12):2551-7.
Score: 0.016